[1][2] In the treatment of SHPT patients on dialysis calcimimetics does not appear to affect the risk of early death.
[3] It does decrease the need for a parathyroidectomy but caused more issues with low blood calcium levels and vomiting.
As a result of the receptor "thinking" there is sufficient calcium, parathyroid hormone (PTH) secretion will be reduced.
Etelcalcetide binds to the CaSR on the parathyroid gland, which results in receptor activation and ultimately reduction in PTH.
Common side effects include: nausea and vomiting, hypocalcemia, and adynamic bone disease if intact parathyroid hormone (iPTH) levels drop below 100pg/mL.